Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Long-Term Investments: 2019-2023

Historic Long-Term Investments for Nurix Therapeutics (NRIX) over the last 5 years, with Nov 2023 value amounting to $7.4 million.

  • Nurix Therapeutics' Long-Term Investments fell 4.15% to $9.5 million in Q3 2024 from the same period last year, while for Aug 2024 it was $9.5 million, marking a year-over-year decrease of 4.15%. This contributed to the annual value of $7.4 million for FY2023, which is 88.38% down from last year.
  • Per Nurix Therapeutics' latest filing, its Long-Term Investments stood at $7.4 million for FY2023, which was down 88.38% from $63.9 million recorded in FY2022.
  • In the past 5 years, Nurix Therapeutics' Long-Term Investments ranged from a high of $137.2 million in FY2021 and a low of $506,000 during FY2019.
  • For the 3-year period, Nurix Therapeutics' Long-Term Investments averaged around $69.5 million, with its median value being $63.9 million (2022).
  • Its Long-Term Investments has fluctuated over the past 5 years, first spiked by 17,862.45% in 2020, then slumped by 88.38% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Long-Term Investments (Yearly) stood at $506,000 in 2019, then surged by 17,862.45% to $90.9 million in 2020, then spiked by 50.94% to $137.2 million in 2021, then crashed by 53.44% to $63.9 million in 2022, then crashed by 88.38% to $7.4 million in 2023.